-
EP1615955
European procedure
Extract from the Register of European Patents
EP About this file: EP1615955
| EP1615955 - ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 02.08.2013 Database last updated on 31.08.2024 | Most recent event Tooltip | 02.08.2013 | No opposition filed within time limit | published on 04.09.2013 [2013/36] | Applicant(s) | For all designated states AbbVie Biotherapeutics Inc. 1500 Seaport Boulevard Redwood City, CA 94063 / US | [2013/12] |
| Former [2012/39] | For all designated states Abbott Biotherapeutics Corp. 1500 Seaport Boulevard Redwood City, CA 94063 / US | ||
| Former [2010/52] | For all designated states Abbott Biotherapeutics Corp. 1500 Seaport Boulevard Redwood City CA 94063 / US | ||
| Former [2009/35] | For all designated states Facet Biotech Corporation 1500 Seaport Boulevard Redwood City, CA 94063 / US | ||
| Former [2007/52] | For all designated states PDL BioPharma, Inc. 1400 Seaport Blvd. Redwood City, CA 94063 / US | ||
| Former [2006/30] | For all designated states PDL BioPharma, Inc. 34801 Campus Drive Fremont, CA 94555 / US | ||
| Former [2006/03] | For all designated states PROTEIN DESIGN LABS, INC. 34801 Campus Drive Fremont, CA 94555 / US | Inventor(s) | 01 /
HINTON, Paul R. 321 Dunsmuir Terrace 4 Sunnyvale, CA 94085 / US | 02 /
TSURUSHITA, Naoya 3719 Redwood Circle Palo Alto, CA 94306 / US | 03 /
TSO, J. Yun 445 Oakgrove Avenue No16 Menlo Park, CA 94025 / US | 04 /
VASQUEZ, Maximiliano 3813 Louis Road Palo Alto, CA 94303 / US | [2006/14] |
| Former [2006/03] | 01 /
HINTON, Paul R. 321 Dunsmuir Terrace 4 Sunnyvale, CA 94085 / US | ||
| 02 /
TSURUSHITA, Naoya 3719 Redwood Circle Palo Alto, CA 94306 / US | |||
| 03 /
TSO, J. Yun 445 Oakgrove Avenue 6 Menlo Park, CA 94025 / US | |||
| 04 /
VASQUEZ, Maximiliano 3813 Louis Road Palo Alto, CA 94303 / US | Representative(s) | Bizley, Richard Edward, et al Avidity IP Broers Building Hauser Forum 21 J J Thomson Ave Cambridge CB3 0FA / GB | [N/P] |
| Former [2012/39] | Bizley, Richard Edward, et al avidity IP Merlin House Falconry Court Baker's Lane Epping, Essex CM16 5DQ / GB | ||
| Former [2006/03] | Bizley, Richard Edward, et al HLBBshaw Merlin House Falconry Court Baker's Lane Epping, Essex CM16 5DQ / GB | Application number, filing date | 04759444.5 | 09.04.2004 | [2006/03] | WO2004US11213 | Priority number, date | US20030462014P | 10.04.2003 Original published format: US 462014 P | US20030475762P | 03.06.2003 Original published format: US 475762 P | US20030499048P | 29.08.2003 Original published format: US 499048 P | US20030687118 | 15.10.2003 Original published format: US 687118 | [2006/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2004092219 | Date: | 28.10.2004 | Language: | EN | [2004/44] | Type: | A2 Application without search report | No.: | EP1615955 | Date: | 18.01.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.10.2004 takes the place of the publication of the European patent application. | [2006/03] | Type: | B1 Patent specification | No.: | EP1615955 | Date: | 26.09.2012 | Language: | EN | [2012/39] | Search report(s) | International search report - published on: | EP | 24.02.2005 | Classification | IPC: | C07K16/00, // (C07K16/28, 16:24) | [2012/39] | CPC: |
C07K16/082 (EP,US);
C07K16/00 (EP,KR,US);
C07H21/04 (KR);
C07K14/00 (KR);
C07K16/249 (EP,US);
C07K16/2809 (EP,US);
C07K16/2833 (EP,US);
C07K16/2866 (EP,US);
C12N15/00 (KR);
|
| Former IPC [2006/03] | C07K16/00, // C07K16/28, C07K16/24 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/03] | Title | German: | ÄNDERUNG DER FCRN-BINDUNDSAFFINITÄTEN ODER DER SERUM-HALBWERTZEITEN VON ANTIKÖRPERN DURCH MUTAGENESE | [2006/03] | English: | ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS | [2006/03] | French: | MODIFICATION D'AFFINITES DE LIAISON POUR FCRN OU DE DEMI-VIES DE SERUM D'ANTICORPS PAR MUTAGENESE | [2006/03] | Entry into regional phase | 04.11.2005 | National basic fee paid | 04.11.2005 | Designation fee(s) paid | 04.11.2005 | Examination fee paid | Examination procedure | 04.11.2005 | Amendment by applicant (claims and/or description) | 04.11.2005 | Examination requested [2006/03] | 15.01.2009 | Despatch of a communication from the examining division (Time limit: M04) | 21.05.2009 | Reply to a communication from the examining division | 21.08.2009 | Despatch of a communication from the examining division (Time limit: M04) | 24.12.2009 | Reply to a communication from the examining division | 21.01.2011 | Despatch of a communication from the examining division (Time limit: M02) | 31.03.2011 | Reply to a communication from the examining division | 16.05.2012 | Communication of intention to grant the patent | 20.08.2012 | Fee for grant paid | 20.08.2012 | Fee for publishing/printing paid | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.01.2009 | Opposition(s) | 27.06.2013 | No opposition filed within time limit [2013/36] | Fees paid | Renewal fee | 26.04.2006 | Renewal fee patent year 03 | 27.04.2007 | Renewal fee patent year 04 | 25.04.2008 | Renewal fee patent year 05 | 29.04.2009 | Renewal fee patent year 06 | 26.04.2010 | Renewal fee patent year 07 | 25.04.2011 | Renewal fee patent year 08 | 25.04.2012 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]US5530101 (QUEEN CARY L [US], et al) [AD] 15-18 * the whole document *; | [A]US5834597 (TSO J YUN [US], et al) [A] 22-24 * column 9, line 30 - line 52 * * figures 1c,1d,2,4 * * claims 6,11 *; | [AD]US6329511 (VASQUEZ MAXIMILIANO [US], et al) [AD] 19-21 * the whole document *; | [XDI]WO02060919 (MEDIMMUNE INC [US], et al) [XD] 1-5,7,9-11,13-15 * page 5, line 8 - page 7, line 11 * * page 14, line 4 - page 17, line 36 * * page 24, line 20 - page 25, line 12 * * claims 1-3,9-11,15 * [I] 16-27; | [X] - HE X-Y ET AL, "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, (19980115), vol. 160, no. 2, ISSN 0022-1767, pages 1029 - 1035, XP002959848 [X] 9,13 * abstract * * table 1 * * figure 5 * | [ID] - GHETIE V ET AL, "INCREASING THE SERUM PERSISTENCE OF AN IGG FRAGMENT BY RANDOM MUTAGENESIS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, (1997), vol. 15, no. 7, ISSN 1087-0156, pages 637 - 640, XP000876642 [ID] 9,13 * abstract * * page 638, column L, paragraph 2 - column R, paragraph 4 * * table 1 * DOI: http://dx.doi.org/10.1038/nbt0797-637 | [AD] - MARTIN W LANCE ET AL, "Crystal structure at 2.8 ANG of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding", MOLECULAR CELL, (200104), vol. 7, no. 4, ISSN 1097-2765, pages 867 - 877, XP002305812 [AD] 1-27 * abstract * * page 874, column R, paragraph 1 - page 875, column L, paragraph 1 * DOI: http://dx.doi.org/10.1016/S1097-2765(01)00230-1 | [PXI] - HINTON PAUL R ET AL, "Engineered human IgG antibodies with longer serum half-lives in primates.", JOURNAL OF BIOLOGICAL CHEMISTRY, (20040220), vol. 279, no. 8, ISSN 0021-9258, pages 6213 - 6216, XP002305813 [PX] 1,3,5-10,12-14 * the whole document * [PI] 2,4,11,16-27 DOI: http://dx.doi.org/10.1074/jbc.C300470200 | Examination | - WARHAM LANCE MARTIN, "PROTEIN-PROTEIN RECOGNITION: The Neonatal Fc Receptor and Immunoglobulin G", THESIS, XX, XX, (20010101), page 248pp, XP009095293 | by applicant | - SIJMONS ET AL., BIO/TECHNOLOGY, (1990), vol. 8, pages 217 - 221 | - PUTLITZ ET AL., BIO/TECHNOLOGY, (1990), vol. 8, pages 651 - 654 | - QUEEN ET AL., IMMUNOL. REV., (1986), vol. 89, pages 49 - 68 |